0908 GMT - Novo Nordisk shares will likely remain under pressure in the near term following disappointing CagriSema weight-loss drug data, Berenberg analysts write. The company still offers superior sales growth until the end of the decade, but its CagriSema woes have brought the patent expiry of semaglutide--the main ingredient in Ozempic and Wegovy--into full focus. "Novo's obesity pipeline remains more limited than Eli Lilly's and the competitive threat of an oral GLP-1 with equivalence to Wegovy weighs heavy." The bank says consensus Wegovy expectations are too high, and notes a growing preference for Lilly's Zepbound over Novo's Wegovy. Berenberg lowers its price target to 610 Danish kroner from 725 kroner and reiterates its hold rating. Shares fall 0.9% to 524 kroner. (dominic.chopping@wsj.com)
(END) Dow Jones Newswires
March 24, 2025 05:08 ET (09:08 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。